



Centre for Biological Engineering		
Document Ref: FSOP048	Issue no v3.1	Issue Date 18-Dec-12

RISK ASSESSMENT REVIEW/REVISION RECORD

Risk Assessment Ref No:	CBE167	Version Number
		4

This risk assessment should be reviewed **annually** or more frequently if there is any change in the work, or if new information becomes available that indicates the assessment may no longer be valid. **This form should be attached to the front of the current version of the risk assessment or to the new version of the risk assessment if one is issued**

The following review has been carried out on the dates indicated and either the assessment remains valid or it has been amended as indicated.	
Name(s) of reviewer: Jenna Davis	Date: 24/02/2020
Signature: 	
Reason for Review: Expansion of bacteria species to be used	
Revision Required (Y/N)	Y
If Yes, give details of the revision: A further Hazard Group 2 organism that was isolated from a wound and therefore clinically relevant to this study is required for experiments, no substitute can be used, the study already uses Hazard Group 2 Laboratory strains and some antibiotic resistant Hazard Group 2 organisms of different species, this strain provides clinical relevance of a target species of bacteria. The strain is unmodified and will not be modified within the study. The organism is a carbapenem resistant strain of <i>E. coli</i> it will be used following the same methods as described for the other organisms and these methods mitigate the risk of working with Hazard Group 2 antibiotic resistant organisms. There is no associated strain number as the sample is provided by Queens Medical Centre, Nottingham – supplied via their pathogen bank. The strain is isolated from a wound swab and is ideal for this study. Like the other bacteria already listed, <i>E. coli</i> can cause disease but treatment is readily available	

Issued by: P.Hourd	Authorised by: R.I.Temple 	Page 1 of 3
--------------------	--	-------------

Centre for Biological Engineering		
Document Ref: FSOP048	Issue no v3.1	Issue Date 18-Dec-12

and the specific antibiotic resistance profile will be supplied on collection from the suppliers and appended to the risk assessment.

Approval:

Instructions for Reviewer:

1. *The completed form should be forwarded to the CBE Quality Manager. NOTE: Significant revision (See Guidelines GN006 & GN007) will require approval by the person supervising the work and subsequent review and approval by the original approving authority. This may require a revised version of the risk assessment to be issued for re-approval.*
2. *Where an annual review concludes that the risk assessment is still valid ie no revision is required, this should be recorded and the completed form forwarded to the CBE Quality Manager.*

Name of Approver: Elizabeth Ratcliffe	Date: 09/03/2020
Position: PI	
Signature: <i>E. Ratcliffe</i>	
Name of Approver: Julie Turner	Date: 29/06/2020
Position: SSDO	
Signature: <i>J Turner</i>	
Name of Approver:	Date:
Position:	
Signature:	
Name of Approver:	Date:

Centre for Biological Engineering		
Document Ref: FSOP048	Issue no v3.1	Issue Date 18-Dec-12

Position:	
Signature:	

Issued by: P.Hourd	Authorised by: R.I.Temple <i>R.I. Temple</i>	Page 3 of 3
--------------------	---	-------------